This Medudy course is a video tutorial for physicians on the topic of “Long-term management and handling of side effects associated with lorlatinib—CNS effects.”
In this video, Dr. Carolin Groß-Ophoff, senior physician in hematology and oncology at the City of Cologne Hospitals, discusses the ALK tyrosine kinase inhibitor lorlatinib, which is approved for the treatment of advanced, ALK-positive non-small cell lung cancer. Due to its high efficacy in the central nervous system, lorlatinib is recommended as the preferred first-line therapy in current guidelines. At the same time, side effects frequently occur during treatment, particularly central nervous system side effects such as changes in mood, cognition, or speech. Since these must be detected and treated early, structured side-effect management—including early education, close monitoring, and individualized treatment adjustments—is particularly important for successful long-term therapy.
Note: All "speakers" appearing in the Medudy videos are AI-based avatars used to improve the didactics of the videos. The people on whom the avatars are based have explicitly consented to their use. All content is based on high-quality scientific sources and is created and reviewed by the Medudy medical team.
This course was developed with the kind support of Pfizer.
By the end of this training session, you will be familiar with:
– the key facts about lorlatinib
– the results of the CROWN study
– details on common CNS side effects
– options for long-term management involving patients and their families
